Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PVH -21.2%, ASTS -10.3%
Other news:
- ACOR -75.1% (Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement)
- GRTS -38.3% (positive data from Phase 2 study; prices $32.5 million offering)
- VERV -34.9% (Updates on its PCSK9 Program)
- GOEV -27.6% (identifies doubt about continuing as a going concern; reports earnings; enters a $30 billion market with multiple commercial vehicle sales in Saudi Arabia) OCGN -7.8% (Announces Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease)
- CIFR -7% (March operational update)
- CVS -5.4% (Medicare Advantage rate update)
- UNH -4.2% (Medicare Advantage rate update)
- ELV -3.8% (Medicare Advantage rate update)
- VEEV -3.1% (CFO departing)
- CNC -2.8% (Medicare Advantage rate update)
- DJT -1.9% (files 10K with FY23 earnings)
- SNDA -1.7% (entered into $75 mln At-The-Market Issuance Sales Agreement)
- ITCI -1.5% (provides patent updates)
- MOH -1.2% (Medicare Advantage rate update)
- WHR -1% (completes major milestone in its portfolio transformation with closing of EMEA transaction)